Another Brand Of Infant Formula Recalled After Botulism Cases

Nara Organics baby formula has been pulled from shelves nationwide after the Centers for Disease Control and Prevention linked the brand to multiple botulism cases in infants. The recall, announced Friday, marks the second major infant formula safety scare this year, reigniting concerns about supply chain vulnerabilities and regulatory oversight in the $4.5 billion baby formula market.

CDC officials confirmed that at least two infants in separate states developed symptoms of infant botulism — a rare but potentially fatal paralytic illness — after consuming Nara Organics powdered formula. The agency urged parents to stop using the product immediately and to consult pediatricians if their babies show signs such as constipation, weak cry, drooping eyelids or difficulty feeding. The Food and Drug Administration has launched an investigation into the manufacturing facility, with early reports suggesting possible contamination at the source.

The recall covers all lots of Nara Organics Infant Formula Stage 1 and Stage 2 sold since January 2026. The company, a fast-growing organic brand based in Austin, Texas, has not yet issued a public statement beyond a brief webpage acknowledging the recall. Retailers including Target, Walmart and Amazon have removed the products from their shelves and online listings.

Botulism spores can survive even in powdered formula processed at high temperatures, making detection difficult. The illness is caused by Clostridium botulinum bacteria, which produce neurotoxins that attack the nervous system. While most infants recover fully with prompt treatment using botulism immune globulin, cases can lead to lengthy hospitalizations and, in rare instances, death. The CDC reports about 100 infant botulism cases annually in the U.S., most linked to contaminated soil or honey — not commercial formula.

This recall follows a 2022 Abbott Nutrition shutdown that triggered a nationwide formula shortage and led to the creation of the FDA's new Office of Critical Foods. Industry analysts note that Nara Organics, which captured 3% of the organic formula market since its 2021 launch, had previously passed all routine inspections. “The fact that a second major brand has been implicated in infant botulism raises serious questions about current testing protocols,” said Dr. Emily Hartmann, a pediatric infectious disease specialist at Johns Hopkins. “We may need more sensitive, real-time pathogen screening at manufacturing lines.”

The FDA is expected to issue a full report within 30 days. Senator Tammy Duckworth, who led hearings after the 2022 crisis, called for an immediate investigation into whether existing safety rules are adequate. Parents are advised to switch to other CDC-approved brands in the interim, but experts warn that the recall could disrupt supply for millions of families. The broader baby formula market — still recovering from the last shortage — now faces another blow to consumer trust.